Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Alzheimer’s disease and related dementias

Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.

Yun Zhang; Huaqiu Chen; Ran Li; Keenan Sterling; Weihong Song

Originally published in Signal transduction and targeted therapy · 2023-06-30

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer's pathogenesis and progression. Aβ has been the prime target for the development of AD therapy. However, the repeated failures of Aβ-targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of Alzheimer's drug has followed the correct course. However, the recent successes of Aβ targeted trials have assuaged those doubts. In this review, we discussed the evolution of the amyloid cascade hypothesis over the last 30 years and summarized its application in Alzheimer's diagnosis and modification. In particular, we extensively discussed the pitfalls, promises and important unanswered questions regarding the current anti-Aβ therapy, as well as strategies for further study and development of more feasible Aβ-targeted approaches in the optimization of AD prevention and treatment.

Conclusions

Since Aβ aggregates act as the unique specific pathological hallmark of AD and play a causative role in the disease development, they are believed as a promising target for Alzheimer’s modification. Most Aβ-targeting drug trials have failed as a consequence by lack of sufficient specificity and accurate translational models, loss of Aβ physiological homeostasis, and failure to be administered during the best therapeutic window. Nevertheless, learning from these failures will be beneficial to the design of better therapeutic approaches.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?